In the first full year of our return to growth, we made good progress in line with our strategy. Results from our new medicines and Emerging Markets accompanied positive news for patients, most recently including regulatory approvals of Enhertu in breast cancer and Calquence in leukaemia.
Pascal Soriot, Executive Director and Chief Executive Officer
Latest presentations
Full-year and Q4 2019 results
We have
167
projects in our pipeline
Our science
At AstraZeneca, science is at the core of everything we do. But more than that, science is who we are.
Corporate Press Release
Full-year and Q4 2019 results
Corporate Press Release